IMARA

imara-logo

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.

#SimilarOrganizations #People #Financial #Website #More

IMARA

Social Links:

Industry:
Biopharma Biotechnology Genetics Health Care Therapeutics

Founded:
2015-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.imaratx.com

Total Employee:
11+

Status:
Active

Contact:
617 231-6021

Total Funding:
144.8 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Font Awesome Apache


Similar Organizations

acrivon-therapeutics-logo

Acrivon Therapeutics

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

adendra-therapeutics-logo

Adendra Therapeutics

Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.

alector-logo

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

apostle-logo

Apostle

Apostle Inc is a provider of innovative technologies and services for public health and life sciences.

arvinas-logo

Arvinas

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

biochip-labs-logo

Biochip Labs

Biochip Labs provides blood disorder testing for conditions like sickle cell disease and thalassemia.

biognosys-logo

Biognosys

Biognosys provides the best possible solutions to support researchers in their protein analysis needs.

celsius-therapeutics-logo

Celsius Therapeutics

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

cleave-therapeutics-logo

Cleave Therapeutics

Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.

cystetic-medicines-logo

Cystetic Medicines

Cystetic Medicines develops a treatment that potentially could help people with cystic fibrosis (CF), regardless of genetic mutation.

kinnate-biopharma-logo

Kinnate Biopharma

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.

liveritas-biosciences-logo

LiVeritas Biosciences

Committed to Truth-telling for Early Success in Drug Development

loxo-oncology-logo

Loxo Oncology

Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.

miadna-logo

MiaDNA

MiaDNA provides people with the genetic information they need to improve their lifestyle and living habits.

nanomosaic-logo

NanoMosaic

NanoMosaic provides solutions for early illness detection, prognostic monitoring, and biomarker identification.

nimbus-therapeutics-logo

Nimbus Therapeutics

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.

nonexomics-logo

NonExomics

NonExomics develops therapeutics to diagnose and cure diseases emanating from the nonexome.

oncoresponse-logo

OncoResponse

OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.

que-oncology-logo

QUE Oncology

QUE Oncology develops novel therapies to address unmet medical needs in the treatment of cancer and its consequences.

refuge-biotechnologies-logo

Refuge Biotechnologies

Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.

regenxbio-logo

REGENXBIO

REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.

swing-therapeutics-logo

Swing Therapeutics

Swing Therapeutics provides digital therapeutics for people with chronic conditions.


Current Advisors List

david-bonita_image

David Bonita Board Member @ Imara
Board_member

carl-goldfischer_image

Carl Goldfischer Board Member @ Imara
Board_member

rahul-ballal_image

Rahul Ballal Board Member @ Imara
Board_member

david-mott_image

David Mott Board Member @ Imara
Board_member
2016-01-01

sara-nayeem_image

Sara Nayeem Board Member @ Imara
Board_member

mette-kirstine-agger_image

Mette Kirstine Agger Board Member @ Imara
Board_member

edward-conner_image

Edward Conner Board Member @ Imara
Board_member
2020-04-01

mark-chin_image

Mark Chin Board Member @ Imara
Board_member

Current Employees Featured

rahul-ballal_image

Rahul Ballal
Rahul Ballal CEO @ Imara
CEO

ashley-jones_image

Ashley Jones
Ashley Jones Vice President, People @ Imara
Vice President, People
2020-12-01

joelle-lufkin_image

Joelle Lufkin
Joelle Lufkin Senior Vice President of Development @ Imara
Senior Vice President of Development

michael-gray_image

Michael Gray
Michael Gray Chief Financial and Chief Operating Officer @ Imara
Chief Financial and Chief Operating Officer
2019-04-01

lynette-hopkinson_image

Lynette Hopkinson
Lynette Hopkinson Senior Vice President of Regulatory @ Imara
Senior Vice President of Regulatory

kenneth-attie_image

Kenneth Attie
Kenneth Attie Senior VP & Chief Medical Officer @ Imara
Senior VP & Chief Medical Officer
2021-01-01

dora-rau_image

Dora Rau
Dora Rau Vice President, Quality Assurance @ Imara
Vice President, Quality Assurance
2019-04-01

frank-waligora_image

Frank Waligora
Frank Waligora Vice President of Technical Operations @ Imara
Vice President of Technical Operations

stephen-migausky_image

Stephen Migausky
Stephen Migausky SVP, Legal & General Counsel @ Imara
SVP, Legal & General Counsel
2020-05-01

Founder


james-mcarthur_image

James McArthur

Stock Details


Company's stock symbol is NASDAQ:IMRA

Investors List

rock-springs-capital_image

Rock Springs Capital

Rock Springs Capital investment in Series B - Imara

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series B - Imara

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Imara

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Imara

arix-bioscience_image

Arix Bioscience

Arix Bioscience investment in Series B - Imara

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series B - Imara

alexandria-venture-investments_image

Alexandria Venture Investments

Alexandria Venture Investments investment in Series B - Imara

lundbeckfond-ventures_image

Lundbeckfonden Ventures

Lundbeckfonden Ventures investment in Series B - Imara

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Series B - Imara

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series A - Imara

Official Site Inspections

http://www.imaratx.com Semrush global rank: 4.29 M Semrush visits lastest month: 2.68 K

  • Host name: 104.21.32.1
  • IP address: 104.21.32.1
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Imara"

Imara - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number 617 231-6021 Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to โ€ฆSee details»

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022 Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enlivenโ€™s portfolio of precision oncology programsCombined company is โ€ฆSee details»

Imara Announces IMR-687 Granted Fast Track Designation and โ€ฆ

Jul 30, 2020 For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans โ€ฆSee details»

Imara Announces Stockholder Approval of Merger With Enliven

Feb 22, 2023 Imara, Inc.-- Combined Company to Trade on Nasdaq Under Ticker โ€œELVNโ€ ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. โ€ฆSee details»

Imara Company Profile - Office Locations, Competitors, Revenue

Feb 27, 2023 Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, โ€ฆSee details»

Imara | VentureRadar

Website: http://www.imaratx.com/ Develops novel therapeutics for sickle cell disease and hemoglobinopathies, including IMR-687, a potent small molecule inhibitor of ...See details»

Imara Announces Pricing of Public Offering - Nasdaq

Jul 14, 2021 Investor Contact: Michael Gray 617-835-4061 [email protected]. Imara, Inc. In This Story IMRA. Market Makers.See details»

IMARA Inc. - Cruelty Free Investing

Company Website: https://imaratx.com Contact: [email protected] ©2024 CrueltyFreeInvesting.org | Cruelty Free Investing is a registered 501c3 Non-Profit Organization โ€ฆSee details»

Enliven Therapeutics and Imara Announce Merger Agreement

Oct 13, 2022 A live webcast of the presentation will be available on the Events & Presentations section of Imaraโ€™s website at https://imaratx.com. A replay of the webcast will be archived on โ€ฆSee details»

Imara Announces Appointment of Laura A. Williams, M.D., MPH

Jun 30, 2021 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans โ€ฆSee details»

Imara to Participate in Upcoming Investor Conferences

Sep 15, 2021 For more information, please visit www.imaratx.com. Media Contact: Marin Bergman Ten Bridge Communications 818-516-2746 [email protected]. โ€ฆSee details»

Imara Announces Appointment of Stephen M. Migausky as โ€ฆ

May 4, 2020 Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare โ€ฆSee details»

Imara TX Application Manager

Example: Funds may support programs and other activities conducted by the organization. -----Additional Information on Imara Advocacy. Real Impact Awards FAQs. Grantor Contact โ€ฆSee details»

Imara Reports Full Year 2021 Financial Results and Business

Mar 15, 2022 The live webcast will be available under โ€œEvents and Presentationsโ€ in the Investors section of the Companyโ€™s website at imaratx.com. The conference call can be โ€ฆSee details»

Imara to Present Clinical Data on IMR-687 as Monotherapy and in ...

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics โ€ฆSee details»

Imara Announces Results of Interim Analyses of Tovinontrine

Apr 5, 2022 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements Statements in this press release about future expectations, plans โ€ฆSee details»

Imara - VentureRadar

Open PageRank: 8,156,814 | imaratx.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the number of times โ€ฆSee details»

Recommended Stories - Yahoo Finance

Mar 29, 2021 Media Contact:Gina NugentTen Bridge [email protected] Investor Contact:Michael Gray617-835 โ€ฆSee details»

Imara Announces Opening of Higher Dose Arms in Global Phase

Mar 17, 2021 For more information, please visit www.imaratx.com. Cautionary Note Regarding Forward-Looking Statements. Statements in this press release about future expectations, โ€ฆSee details»

Imara to Report Data Demonstrating the Potential of Tovinontrine โ€ฆ

Nov 8, 2021 Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by โ€ฆSee details»

linkstock.net © 2022. All rights reserved